文献速递艾滋病与性传播感染

洛匹那韦/利托那韦单药治疗病毒学抑制HIV感染者的96周疗效:一项随机非劣效性试验(ANRS 140 DREAM)

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

在病毒学抑制的HIV感染者中,比较洛匹那韦/利托那韦单药与依非韦伦/恩曲他滨/替诺福韦单片方案96周疗效。意向性分析中,洛匹那韦/利托那韦组64%与单片方案组71%达到主要终点,差异为-6.8%(95% CI下限-19.9%),未达非劣效性。洛匹那韦/利托那韦组罕见出现蛋白酶抑制剂耐药,未损害后续蛋白酶抑制剂选择,两组均无意外严重临床事件。

要点

  • 洛匹那韦/利托那韦单药不能被认为非劣于依非韦伦/恩曲他滨/替诺福韦单片方案。
  • 洛匹那韦/利托那韦组4例出现蛋白酶抑制剂突变,单片方案组2例出现逆转录酶抑制剂突变。
  • 两年洛匹那韦/利托那韦单药与单片方案相比无不良临床影响。

核心结论

  • 洛匹那韦/利托那韦单药不能被认为非劣于依非韦伦/恩曲他滨/替诺福韦单片方案。
  • 洛匹那韦/利托那韦组罕见出现蛋白酶抑制剂耐药,未损害未来蛋白酶抑制剂选择。
  • 与依非韦伦/恩曲他滨/替诺福韦单片方案相比,两年洛匹那韦/利托那韦单药无不良临床影响。

研究设计与样本

  • 随机非劣效性试验,纳入过去12个月血浆HIV-1 RNA病毒载量<50拷贝/mL且无 documented 治疗失败的稳定抗逆转录病毒治疗成人。
  • 受试者随机接受洛匹那韦/利托那韦单药或依非韦伦/恩曲他滨/替诺福韦单片方案治疗2年。
  • 主要终点为第96周无治疗失败的患者比例(第96周病毒载量<50拷贝/mL且第98周确认),无研究治疗中断、新发艾滋病定义疾病或死亡。
  • 意向性分析中洛匹那韦/利托那韦组n=98,依非韦伦/恩曲他滨/替诺福韦组n=97。

主要发现

  • 意向性分析中,洛匹那韦/利托那韦组64%与依非韦伦/恩曲他滨/替诺福韦组71%达到主要终点,差异为-6.8%(95%双侧CI下限:-19.9%)。
  • Sanger和UltraDeep测序显示,洛匹那韦/利托那韦组4例出现蛋白酶抑制剂突变,依非韦伦/恩曲他滨/替诺福韦组2例出现非核苷类逆转录酶抑制剂和/或核苷类逆转录酶抑制剂突变。
  • 未发生意外严重临床事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sparing of antiretroviral drug classes could reduce the toxicity and cost of maintenance treatment for HIV infection. OBJECTIVES: To evaluate the non-inferiority of efficacy and the safety of lopinavir/ritonavir (r) monotherapy versus a single-tablet regimen of efavirenz, emtricitabine and tenofovir (EFV/FTC/TDF) over 2 years. METHODS: Adults on stable ART with plasma HIV-1 RNA viral load <50 copies/mL for the past 12 months and no documented treatment failure were randomized to receive either lopinavir/r or EFV/FTC/TDF for 2 years. The primary endpoint was the proportion of patients without treatment failure at week 96 (viral load <50 copies/mL at week 96, confirmed at week 98), without study treatment discontinuation, a new AIDS-defining illness, or death. RESULTS: In the ITT analysis, the primary endpoint was reached by, respectively, 64% and 71% of patients in the lopinavir/r (n = 98) and EFV/FTC/TDF arms (n = 97), yielding a difference of -6.8% (lower limit of the 95% two-sided CI: -19.9%). Sanger and UltraDeep sequencing showed the occurrence of PI mutations in the lopinavir/r arm (n = 4) and of NNRTI and/or NRTI mutations in the EFV/FTC/TDF arm (n = 2). No unexpected serious clinical events occurred. CONCLUSIONS: Lopinavir/r monotherapy cannot be considered non-inferior to EFV/FTC/TDF. PI resistance rarely emerged in the lopinavir/r arm and did not undermine future PI options. Two years of lopinavir/r monotherapy had no deleterious clinical impact when compared with EFV/FTC/TDF.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Meynard JL, Moinot L, Landman R, et al. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM). J Antimicrob Chemother. 2018. PMID: 29584910. doi:10.1093/jac/dky055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。